OncoMatch/Clinical Trials/NCT05250648
Clinical Trial on HIPEC with Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)
Is NCT05250648 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes for peritoneal carcinomatosis.
Treatment: complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes — The aim of this study is to assess whether there are differences in PERITONEAL RECURRENCE in patients with Colon Cancer Peritoneal Metastases treated with complete surgical resection and systemic chemotherapy, with (Group 1) or without (Group 2) HIPEC with Mitomycin-C.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Colorectal Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic chemotherapy — perioperative (before and/or after surgery)
Treatment with perioperative systemic chemotherapy (SCT), before and/or after surgical procedure.
Cannot have received: HIPEC
Patients previously treated with HIPEC.
Lab requirements
Blood counts
No severe alterations in hematological function (operable patients)
Kidney function
No severe alterations in renal function (operable patients)
Liver function
No severe alterations in hepatic function (operable patients)
Cardiac function
No severe alterations in cardiac function (operable patients)
No severe alterations in hematological, renal, cardiac, pulmonary or hepatic function (operable patients).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify